You can buy Sotoldx at the lowest price in the online pharmacy Nextgen.ooo . Sotorasib is a KRAS inhibitor that is being studied for the treatment of non-small cell lung cancer with the KRAS G12C mutation, colorectal cancer, and appendiceal cancer. Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated for the treatment of adult patients with non-small cell lung cancer with the KRAS G12C mutation. This mutation accounts for >50% of all KRAS mutations. The KRAS mutant was discovered in 1982, but was not considered a drug target until the mid-2010s. It is the first experimental KRAS inhibitor. MRTX849 is also currently in development and has the same target. Sotorasib received FDA approval on May 28, 2021, followed by European Commission approval on January 10, 2022.
 
Sotorasib is indicated for the treatment of adults with KRAS G12C-mutated non-small cell lung cancer. It has a moderate duration of action because it is taken daily.
Normally, GTP binds to KRAS, activating the protein and stimulating MAP kinase pathway effectors. GTP is hydrolyzed to GDP, and KRAS is inactivated. KRAS G12C mutations impair GTP hydrolysis, leaving it in its active form.
 
Sotorasib binds to a cysteine ​​residue in KRAS G12C mutations, keeping the protein in its inactive form. The cysteine ​​residue that sotorasib targets is not present in wild-type KRAS, preventing side effects. This mutation is present in 13% of non-small cell lung cancer, 3% of colorectal and appendiceal cancer, and 1-3% of solid tumors.